Thromboembolism

Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, is Director of the BWH Venous Thromboembolism Research Group. He has been the Principal Investigator for multiple deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment trials, including 5 multicenter PE thrombolysis trials. He is Chair of the Steering Committee of the NIH-sponsored multicenter ATTRACT Trial, which is studying the optimal method to manage massive DVT. He is especially interested in improving venous thromboembolism prophylaxis of at-risk hospitalized patients. In the March 10, 2005 New England Journal of Medicine, he published a 2,500 patient randomized clinical trial which described a new physician alert strategy to reduce symptomatic DVT and PE by 41%. He is currently conducting another 2,500 patient randomized clinical trial at 26 institutions across the United States to determine whether these positive results are reproducible outside of Brigham and Women’s Hospital.

Dr. Goldhaber is Principal Investigator of about a dozen ongoing randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of PE and DVT. As Founder and Director of the BWH Anticoagulation Service, which cares for more than 2,100 active patients, he is also conducting research on optimal warfarin dosing. He is Chair of the Steering Committee of the ADOPT Trial, which is studying the safety and efficacy of a new oral anticoagulant for prophylaxis of venous thromboembolism in acutely ill medical subjects during and following hospitalization. Dr. Goldhaber is also Principal Investigator of an observational trial exploring new ways to foster venous thromboembolism prophylaxis at the time of hospital discharge. He encourages Vascular Medicine Fellows to participate in these research projects.

Dr. Goldhaber is committed to promoting outreach to other health care professionals as well as to the lay public. He helped found and is President of the North American Thrombosis Forum, a nonprofit organization. He chairs the Steering Committee of the Venous Disease Coalition, another nonprofit initiative, run by the Vascular Disease Foundation.

References

Fanikos J, Cina J, Baroletti S, Fiumara K, Matta L, Goldhaber SZ. Adverse drug events in hospitalized cardiac patients. Am J Cardiol 2007; 100: 1465-1469.

Hunsaker AR, Zou KH, Poh AC, Trotman-Dickenson B, Jacobson FL, Gill RR Goldhaber SZ. Routine pelvic and lower extremity CT venography in patients undergoing pulmonary CT angiography. AJR 2008; 190: 322-328.

Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006;113:577-582.

Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 969-977.

Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. CHEST 2007; 132: 554-561.

Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: A predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-3280 .

Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656-661.

Shetty R, Seddighzadeh A, Piazza G, Goldhaber, SZ. Chronic obstructive pulmonary disease and deep vein thrombosis: A prevalent combination. J Thromb Thrombolysis 2007; epublished October 17.

Shetty R, Seddighzadeh A, Parasuraman S, Vallurupalli NG, Gerhard-Herman M, Goldhaber SZ. Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism. Thromb Haemost 2007; 98: 1384-1386.